Online Program Home
My Program

Abstract Details

Activity Number: 20 - Statistical Considerations for Using Historical Controls in Clinical Trials
Type: Topic Contributed
Date/Time: Sunday, July 29, 2018 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #329758 Presentation
Title: Advancing Methodologies for Clinical Trials Using Historical Control
Author(s): Min Min* and Yeh-Fong Chen
Companies: U.S. Food and Drug Administration, CDER/OTS/OB and US FDA
Keywords: historical controls; rare diseases

Enrolling adequate patients in clinical trials for rare diseases can be challenging. Therefore, historical controls obtained through well conducted natural history studies may be considered. In recent years, FDA has approved therapies using historical controls, including asfotase alfa for perinatal/infantile- and juvenile-onset hypophosphatasia (HPP) in 2015 and cerliponase alfa for CLN2 disease in 2017. When considering historical controls, concerns include: the comparability of baseline characteristics and assessments in the proposed intervention and historical controls; and the ability to minimize bias due to the non-randomized setting. Potential confounders need to be considered and missing data in the natural history study may also be relevant. To overcome these challenges, we must carefully examine the data using different statistical methods and models. A robust well constructed sensitivity analysis plan is needed to evaluate the trial evidence. Several statistical and graphical methods will be used to illustrate potential solutions, including covariate-adjusted survival analyses; matching analyses using propensity scores; Fisher's exact and McNemar tests.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program